These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 17548898)
1. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors. Siminerio L Diabetes Educ; 2007; 33 Suppl 5():111S-3S. PubMed ID: 17548898 [No Abstract] [Full Text] [Related]
2. Emerging treatments for patients with type 2 diabetes. Haines ST Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897 [No Abstract] [Full Text] [Related]
3. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Deacon CF Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200 [TBL] [Abstract][Full Text] [Related]
4. Sitagliptin: a viewpoint by Mark S. Kipnes. Kipnes MS Drugs; 2007; 67(4):598-9. PubMed ID: 17352517 [No Abstract] [Full Text] [Related]
5. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Green BD; Flatt PR; Bailey CJ Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910 [TBL] [Abstract][Full Text] [Related]
11. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Ahrén B Expert Opin Investig Drugs; 2006 Apr; 15(4):431-42. PubMed ID: 16548792 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Nauck MA; El-Ouaghlidi A Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719 [No Abstract] [Full Text] [Related]
13. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Mest HJ; Mentlein R Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466 [TBL] [Abstract][Full Text] [Related]
14. Gut hormones and related concepts. Bloomgarden ZT Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315 [No Abstract] [Full Text] [Related]
15. New drugs for the treatment of type 2 diabetes. Chowdhury TA; Hossain B Br J Hosp Med (Lond); 2007 Apr; 68(4):178-83. PubMed ID: 17465090 [TBL] [Abstract][Full Text] [Related]
16. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE; Lau J; Pittas AG JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601 [TBL] [Abstract][Full Text] [Related]
18. The physiology of incretin hormones and the basis for DPP-4 inhibitors. McKennon SA; Campbell RK Diabetes Educ; 2007; 33(1):55-6, 60-2, 65-6. PubMed ID: 17272793 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Pratley RE; Salsali A Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649 [TBL] [Abstract][Full Text] [Related]
20. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Barnett A; Allsworth J; Jameson K; Mann R Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]